Bortezomib for the Treatment of Hematologic Malignancies: 15 Years Later

Abstract Bortezomib is a dipeptidyl boronic acid that selectively inhibits the ubiquitin proteasome pathway, which plays a role in the degradation of many intracellular proteins. It is the first-in-class selective and reversible inhibitor of the 26S proteasome, with antiproliferative and antitumor a...

Full description

Saved in:
Bibliographic Details
Main Authors: Pawel Robak (Author), Tadeusz Robak (Author)
Format: Book
Published: Adis, Springer Healthcare, 2019-04-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

Connect to this object online.

3rd Floor Main Library

Holdings details from 3rd Floor Main Library
Call Number: A1234.567
Copy 1 Available